PSA after radiation for prostate cancer

ONCOLOGY

Volumn 18, Issue 5, 2004, Pages 595-604

  Kuban, Deborah A ^a   Thames, Howard D ^a   Levy, Larry B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; BRACHYTHERAPY; HUMAN; MALE; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; PROSTATE TUMOR; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

BRACHYTHERAPY; HUMANS; MALE; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

EID: 16544377917     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Kuban DA, EI-Mahdi AM, Schellhammer PF: Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 32:307-316, 1995.
2. Horwitz EM, Vicini FA, Ziaja E, et al: Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 36:565-571, 1996.
3. Kuban DA, el-Mahdi AM, Schellhammer PF: PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: Do we know how to use it? Semin Radiat Oncol 8:72-80, 1998.
4. Wilett CG, Zietman AL, Shipley WU, et al: The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 151:1579-1581, 1994.
5. McLaughlin PW, Sandler HN, Jiroutek MR: Prostate-specific antigen following prostate radiotherapy: How low can you go? J Clin Oncol 14:2889-2892, 1996.
6. Zietman AL, Tibbs MK, Dallow KC, et al: Use of PS A nadir to predict subsequent biochemical outcome following external beam radiation therapy for Tl-2 adenocarcinoma of the prostate. Radiother Oncol 40:159-162, 1996.
7. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement: Guidelines for PSA following radiation therapy. IntJ Radiat Oncol Biol Phys 37:1035-1041, 1997.
8. Shipley WU, Thames HW, Sandler HM, et al: Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 281:1598-1604, 1999.
9. Taylor JMG, Griffith KA, Sandler HM: Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 50:1212-1219, 2001.
10. Pickles T, Duncan GG, Kim-Sing C, et al: PSA relapse definitions: The Vancouver rules show superior predictive power. Int J Radial Oncol Biol Phys 43:699-700, 1999.
11. Critz FA: A standard definition of disease freedom is needed for prostate cancer: Undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology Consensus Definition. J Urol 167:1310-1313, 2002.
12. Vicini FA, Kestin LL, Martinez AA: The importance of adequate follow-up in defining treatment success after external-beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 45:553-561, 1999.
13. Horwitz EM, Uzzo RG, Hanlon AL, et al: Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimenional conformal radiation therapy alone. J Urol 169:2153-2159, 2003.
14. Kattan MW, Fearn PA, Leibei S, et al: The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 48:1469-1474, 2000.
15. Gretzer MB, Trock BJ, Han M, et al: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 168:1419-1422, 2002.
16. Kuban DA, Thames HD, Levy LB, et al: Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radio herapy in the PSA era. Int J Radiat Oncol Biol Phys 57:915-928, 2003.
17. Thames H, Kuban D, Levy L, et al: Comparison of alternative biochemical failure definitions based on clinical outcome in 4, 839 prostate cancer patients treated by external-beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57:929-943, 2003.
18. Aref I, Eapen L, Agboola O, et al: The relationship between biochemical failure and time to nadir in patients treated with external- beam therapy for T1-T3 prostate carcinoma. Radiother Oncol 48:203-207, 1998.
19. Hanlon AL, Diratzouian H, Hanks GE: Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53:297-303, 2002.
20. Hanlon AL, Hanks GE: Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. Int J Radiat Oncol Biol Phys 46:559-566, 2000.
21. Jani AB, Chen MH, Vaida F, et al: PSA- based outcome analysis after radiation therapy for prostate cancer: A new definition of biochemical failure after intervention. Urology 54:700-705, 1999.
22. Arming CL, Bergstralh EJ, Blute ML, et al: Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 165:1146-1151, 2001.